Trials / Recruiting
RecruitingNCT03460379
Bariatric Surgery and Pharmacokinetics of Escitalopram
Bariatric Surgery and Pharmacokinetics Escitalopram: BAR-MEDS Escitalopram
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 12 (estimated)
- Sponsor
- Norwegian University of Science and Technology · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on escitalopram are investigated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Escitalopram | Patients are tested for their normal prescription escitalopram medication |
Timeline
- Start date
- 2016-11-02
- Primary completion
- 2026-10-01
- Completion
- 2026-10-01
- First posted
- 2018-03-09
- Last updated
- 2023-03-27
Locations
1 site across 1 country: Norway
Source: ClinicalTrials.gov record NCT03460379. Inclusion in this directory is not an endorsement.